Word: researchers
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...paralyzing the facial muscles used for frowning, Botulinum Toxin A - or Botox - prevents people from physically displaying expressions of negative emotion. Building on previous research that suggests facial expressions not only reflect but influence mood levels, the new study hypothesizes that Botox may lighten people's moods by literally wiping the frowns off their faces. (Read "The Year in Medicine 2008: From...
...Lewis says he favors the theory that facial muscles influence brain activity directly and points to earlier research that suggests such a neurological link. For example, studies have shown that subjects find comedy routines significantly funnier when they hold a pen between their teeth the way a dog holds a bone, a pose that stimulates the muscles used for smiling. Similarly, subjects laugh less when holding a pen between their lips, a pose that mimics frowning...
...While the cosmetic industry did not fund Lewis' study, it will probably get a boost from his new Botox research. The industry has already shown interest in promoting Botox as a mood enhancer: "I have noted frequently that my patients who receive Botox seem happier," Joel Schlessinger, then president-elect of the American Society of Cosmetic Dermatology and Aesthetic Surgery and president of LovelySkin.com, said in 2006. And Botox has already proved to be somewhat of a wonder drug in its wide application: studies have shown it to be an effective treatment for enlarged prostates, migraines, excessive sweating, writer...
...says, to consider Botox injections - at around $400 each - purely on the basis of their potential for mood enhancement. "The problem is that Botox paralyzes muscles used for communication - even if it is negative communication - so it's difficult to predict the full consequences," he says. "But certainly the research suggests possible treatments." And that, at least, could be something to smile about...
...published on Mar. 1, outlined good reasons for Harvard’s involvement with private pharmaceutical companies. It demonstrated a vital engagement with the national conversation about the best means to ensure global access—particularly in the developing world—to the fruits of medical research performed within the academic community. This was accompanied by a call to deliver essential medicines to the developing world at a symposium held at Harvard Law School this week. Harvard should maintain momentum in its quest for new therapies and new strategies aimed at their broad dissemination especially to those...